Zai Lab Announces Breakthrough Therapy Designation Granted for Repotrectinib in China

Zai Lab Limited announced that the Center for Drug Evaluation of the National Medical Products Administration granted Breakthrough Therapy Designation for investigational repotrectinib for the treatment of patients with ROS1-positive metastatic NSCLC who have not been treated with a ROS1 tyrosine kinase inhibitor.